Although therapy with checkpoint inhibitors, particularly anti-PD-1/PD-L1 and anti-CTLA-4 mAbs, has demonstrated marked success in recovering anti-tumor immune responses and improving the survival of patients with advanced malignancy, the response rates are only approximately 20 to 40% using given a checkpoint inhibitor alone (122). The gene discussed is PDCD1; the disease is neoplasm.